CytoBay Inc.
CytoBay Inc. is a platform company focused on AI-facilitated cancer diagnosis using cytology specimens. Their core technology, Liquid Immunocytochemistry (LICC), is a patented process that stains tumor markers with high accuracy, allowing for the simultaneous evaluation of both morphology and tumor marker expression on a single cytology slide. This enables pathologists to produce accurate evaluations on patient liquid samples. CytoBay's flagship product is an automated LICC machine designed for high throughput and a 3-hour turnaround time, coupled with an AI interface for enumerating suspicious tumor cells. They also offer at-home screening kits, powered by AI-generated risk assessments, for convenient and early cancer detection. Their vision is to treat cancer as a chronic illness through accurate and accessible screening, with an initial focus on bladder cancer screening and recurrence monitoring.
CytoBay Inc.
CytoBay Inc. is a platform company focused on AI-facilitated cancer diagnosis using cytology specimens. Their core technology, Liquid Immunocytochemistry (LICC), is a patented process that stains tumor markers with high accuracy, allowing for the simultaneous evaluation of both morphology and tumor marker expression on a single cytology slide. This enables pathologists to produce accurate evaluations on patient liquid samples. CytoBay's flagship product is an automated LICC machine designed for high throughput and a 3-hour turnaround time, coupled with an AI interface for enumerating suspicious tumor cells. They also offer at-home screening kits, powered by AI-generated risk assessments, for convenient and early cancer detection. Their vision is to treat cancer as a chronic illness through accurate and accessible screening, with an initial focus on bladder cancer screening and recurrence monitoring.